泛素连接酶抑制剂的鉴定策略。
Strategies for the identification of ubiquitin ligase inhibitors.
机构信息
Progenra Inc., 271A Great Valley Parkway, Malvern, PA 19355, USA.
出版信息
Biochem Soc Trans. 2010 Feb;38(Pt 1):132-6. doi: 10.1042/BST0380132.
Abstract
Dysregulation of the UPS (ubiquitin-proteasome system) has been implicated in a wide range of pathologies including cancer, neurodegeneration and viral infection. Inhibiting the proteasome has been shown to be an effective therapeutic strategy in humans; however, toxicity with this target remains high. E3s (Ub-protein ligases) represent an alternative attractive therapeutic target in the UPS. In this paper, we will discuss current platforms that report on E3 ligase activity and can detect E3 inhibitors, and underline the advantages and disadvantages of each approach.
摘要
UPS（泛素-蛋白酶体系统）的失调与多种疾病有关，包括癌症、神经退行性疾病和病毒感染。抑制蛋白酶体已被证明是人类的一种有效治疗策略；然而，该靶点的毒性仍然很高。E3s（泛素蛋白连接酶）是 UPS 中另一个有吸引力的治疗靶点。在本文中，我们将讨论目前报告 E3 连接酶活性并能检测 E3 抑制剂的平台，并强调每种方法的优缺点。
相似文献
1
Strategies for the identification of ubiquitin ligase inhibitors.
Biochem Soc Trans. 2010 Feb;38(Pt 1):132-6. doi: 10.1042/BST0380132.
2
A patent review of the ubiquitin ligase system: 2015-2018.
Expert Opin Ther Pat. 2018 Dec;28(12):919-937. doi: 10.1080/13543776.2018.1549229. Epub 2018 Nov 23.
3
Strategies for the identification of novel inhibitors of deubiquitinating enzymes.
Biochem Soc Trans. 2008 Oct;36(Pt 5):828-32. doi: 10.1042/BST0360828.
4
Therapeutic strategies within the ubiquitin proteasome system.
Cell Death Differ. 2010 Jan;17(1):4-13. doi: 10.1038/cdd.2009.82.
5
Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
Oncotarget. 2014 Sep 30;5(18):7988-8013. doi: 10.18632/oncotarget.2431.
6
Ubiquitination and deubiquitination: Implications on cancer therapy.
Biochim Biophys Acta Gene Regul Mech. 2023 Dec;1866(4):194979. doi: 10.1016/j.bbagrm.2023.194979. Epub 2023 Aug 24.
7
The ubiquitin system, disease, and drug discovery.
BMC Biochem. 2008 Oct 21;9 Suppl 1(Suppl 1):S7. doi: 10.1186/1471-2091-9-S1-S7.
8
Cullin 5-RING E3 ubiquitin ligases, new therapeutic targets?
Biochimie. 2016 Mar;122:339-47. doi: 10.1016/j.biochi.2015.08.003. Epub 2015 Aug 4.
9
Mapping the interactome of HPV E6 and E7 oncoproteins with the ubiquitin-proteasome system.
FEBS J. 2017 Oct;284(19):3171-3201. doi: 10.1111/febs.14193. Epub 2017 Aug 29.
10
Targeting the ubiquitin system in cancer therapy.
Nature. 2009 Mar 26;458(7237):438-44. doi: 10.1038/nature07960.
引用本文的文献
1
TRIP12's role in the governance of DNA polymerase β involvement in DNA damage response and repair.
Nucleic Acids Res. 2025 Jun 20;53(12). doi: 10.1093/nar/gkaf574.
2
Modulation of Lonp1 Activity by Small Compounds.
Biomolecules. 2025 Apr 9;15(4):553. doi: 10.3390/biom15040553.
3
Praja1 RING-finger E3 ubiquitin ligase suppresses neuronal cytoplasmic TDP-43 aggregate formation.
Neuropathology. 2020 Dec;40(6):570-586. doi: 10.1111/neup.12694. Epub 2020 Jul 19.
4
Znf179 E3 ligase-mediated TDP-43 polyubiquitination is involved in TDP-43- ubiquitinated inclusions (UBI) (+)-related neurodegenerative pathology.
J Biomed Sci. 2018 Nov 8;25(1):76. doi: 10.1186/s12929-018-0479-4.
5
Real-time tracking of complex ubiquitination cascades using a fluorescent confocal on-bead assay.
BMC Biol. 2018 Aug 10;16(1):88. doi: 10.1186/s12915-018-0554-z.
6
A novel reporter for real-time, quantitative imaging of AKT-directed K63-poly-ubiquitination in living cells.
Oncotarget. 2018 Jan 25;9(13):11083-11099. doi: 10.18632/oncotarget.24323. eCollection 2018 Feb 16.
7
Alterations in the E3 ligases Parkin and CHIP result in unique metabolic signaling defects and mitochondrial quality control issues.
Neurochem Int. 2018 Jul;117:139-155. doi: 10.1016/j.neuint.2017.08.013. Epub 2017 Aug 26.
8
E3 Ubiquitin Ligases Neurobiological Mechanisms: Development to Degeneration.
Front Mol Neurosci. 2017 May 19;10:151. doi: 10.3389/fnmol.2017.00151. eCollection 2017.
9
Unravelling druggable signalling networks that control F508del-CFTR proteostasis.
Elife. 2015 Dec 23;4:e10365. doi: 10.7554/eLife.10365.
10
Role of E3 ubiquitin ligases in gastric cancer.
World J Gastroenterol. 2015 Jan 21;21(3):786-93. doi: 10.3748/wjg.v21.i3.786.
本文引用的文献
1
Cell death: protein misfolding and neurodegenerative diseases.
Apoptosis. 2009 Apr;14(4):455-68. doi: 10.1007/s10495-008-0301-y.
2
Molecular basis of Pirh2-mediated p53 ubiquitylation.
Nat Struct Mol Biol. 2008 Dec;15(12):1334-42. doi: 10.1038/nsmb.1521. Epub 2008 Nov 30.
3
The malin-laforin complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system.
Hum Mol Genet. 2009 Feb 15;18(4):688-700. doi: 10.1093/hmg/ddn398. Epub 2008 Nov 25.
4
Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
Expert Opin Investig Drugs. 2008 Dec;17(12):1865-82. doi: 10.1517/13543780802493366.
5
The involvement of the ubiquitin proteasome system in human skeletal muscle remodelling and atrophy.
Biochim Biophys Acta. 2008 Dec;1782(12):730-43. doi: 10.1016/j.bbadis.2008.10.011. Epub 2008 Oct 29.
6
The ubiquitin-proteasome system in spongiform degenerative disorders.
Biochim Biophys Acta. 2008 Dec;1782(12):700-12. doi: 10.1016/j.bbadis.2008.08.006. Epub 2008 Aug 23.
7
Aberrant methylation of the HACE1 gene is frequently detected in advanced colorectal cancer.
Anticancer Res. 2008 May-Jun;28(3A):1581-4.
8
The HECT family of E3 ubiquitin ligases: multiple players in cancer development.
Cancer Cell. 2008 Jul 8;14(1):10-21. doi: 10.1016/j.ccr.2008.06.001.
9
Itch: a HECT-type E3 ligase regulating immunity, skin and cancer.
Cell Death Differ. 2008 Jul;15(7):1103-12. doi: 10.1038/cdd.2008.60.
10
CARPs enhance p53 turnover by degrading 14-3-3sigma and stabilizing MDM2.
Cell Cycle. 2008 Mar 1;7(5):670-82. doi: 10.4161/cc.7.5.5701. Epub 2008 Jan 31.
Zotero 插件